Formoterol

BRAND NAMES

1. Foradil (formoterol inhalation capsules/inhaler) 

2. Oxis (Oxis Turbohaler in many countries) 

3. Foracort (combination of formoterol + budesonide) 

4. Symbicort (formoterol + budesonide inhaler; widely used globally) 

5. Fostair (formoterol + beclometasone combination inhaler in some regions).

MECHANISM OF ACTION

Formoterol is a long-acting β2-adrenergic receptor agonist (LABA) that produces bronchodilation by selectively stimulating β2 receptors on bronchial smooth muscle. This activation stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) levels, which leads to activation of protein kinase A and subsequent relaxation of smooth muscle cells. As a result, bronchial constriction is reduced and airflow is improved.

PHARMACOKINETICS

Absorption:
Formoterol is well absorbed after inhalation via the respiratory tract, where it acts directly on bronchial smooth muscle. A portion of the inhaled dose is swallowed and absorbed from the gastrointestinal tract, but this contributes minimally to systemic activity due to first-pass metabolism. Peak plasma concentrations are typically reached within minutes to a few hours, depending on the formulation.

Distribution:
Formoterol is moderately lipophilic and distributes widely in body tissues after absorption. It shows moderate plasma protein binding and is primarily concentrated in the lungs, which is its main site of action.

Metabolism:
Formoterol is extensively metabolized in the liver, mainly through direct glucuronidation and O-demethylation pathways. These metabolic processes produce inactive metabolites, reducing systemic pharmacological activity.

Elimination:
The drug and its metabolites are eliminated primarily through urine, with a smaller portion excreted in feces. The elimination half-life supports its prolonged bronchodilator effect, lasting approximately 10–12 hours after inhalation.

PHARMACODYNAMICS

Formoterol is a long-acting β2-adrenergic receptor agonist (LABA) that produces bronchodilation by selectively stimulating β2 receptors located on bronchial smooth muscle. Activation of these receptors stimulates adenylate cyclase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP activates protein kinase A, which reduces intracellular calcium concentration and promotes relaxation of airway smooth muscle. 

ADMINISTRATION

Formoterol is administered by inhalation, either as a dry powder inhaler (DPI) or as part of a metered-dose inhaler (MDI), and is also available in combination inhalers with inhaled corticosteroids. It is used for long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), and should be taken regularly as prescribed rather than only for acute symptom relief. 

DOSAGE AND STRENGTH

Formoterol dosing depends on the formulation and indication. For adults with asthma or COPD, typical maintenance doses range from 6 mcg to 12 mcg inhaled twice daily, depending on the specific inhaler product. In combination inhalers (e.g., with budesonide or beclometasone), dosing is based on fixed-dose combinations delivered once or twice daily.

DRUG INTERACTIONS

Formoterol may interact with other sympathomimetic agents, increasing the risk of cardiovascular side effects such as tachycardia and hypertension. Beta-blockers can reduce its bronchodilatory effect and may precipitate bronchospasm in susceptible patients. 

FOOD INTERACTIONS

Formoterol has no significant clinically relevant food interactions. It is administered via inhalation, so food does not affect its absorption or therapeutic effect.

CONTRAINDICATIONS

Formoterol is contraindicated in patients with known hypersensitivity to formoterol or any component of the formulation. It should not be used as monotherapy in asthma without an inhaled corticosteroid due to an increased risk of asthma-related adverse outcomes.

SIDE EFFECTS

1. Tremor  

2. Headache  

3. Palpitations  

4. Tachycardia  

5. Muscle cramps 

6. Nervousness or restlessness 

7. Hypokalemia (low potassium levels) 

8. Throat irritation (inhaled use) 

9. Rare: paradoxical bronchospasm.

OVER DOSAGE

Formoterol overdose results from excessive β2-adrenergic stimulation and is usually associated with exaggerated pharmacological effects rather than direct toxicity. It may occur due to excessive inhalation or use above the recommended dose, especially in combination inhaler misuse.

TOXICITY

Formoterol toxicity is mainly related to excessive β2-adrenergic stimulation. Symptoms may include severe tachycardia, hypertension, tremors, hypokalemia, hyperglycemia, and in severe cases, cardiac arrhythmias